Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.
2.

The HIV-Brazil cohort study: design, methods and participant characteristics.

Grangeiro A, Escuder MM, Cassenote AJ, Souza RA, Kalichman AO, Veloso VG, Ikeda ML, Barcellos NT, Brites C, Tupinanbás U, Lucena NO, da Silva CL, Lacerda HR, Grinsztejn B, Castilho EA.

PLoS One. 2014 May 1;9(5):e95673. doi: 10.1371/journal.pone.0095673. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e104119. Cassanote, Alex Jones Flores [corrected to Cassenote, Alex Jones Flores]; Veloso, Valdiléa [corrected to Veloso, Valdiléa G].

3.

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group.

PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

4.

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team.

J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4.

5.

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR; NIAID HIV Vaccine Trials Network.

PLoS One. 2012;7(1):e29231. doi: 10.1371/journal.pone.0029231. Epub 2012 Jan 5.

6.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

7.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

8.

AIDS treatment in Brazil: what kind of evidence do we need?

Kalichman AO, Diniz SG.

Lancet. 2009 Sep 26;374(9695):1066. doi: 10.1016/S0140-6736(09)61705-0. No abstract available.

PMID:
19782871
9.

Debate on the paper by David Vlahov & David D. Celentano.

Kalichman A.

Cad Saude Publica. 2006 Apr;22(4):727-8; author reply 730-1. Epub 2006 Apr 5. No abstract available.

10.

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3.

Lewi DS, Suleiman JM, Uip DE, Pedro RJ, Souza RA, Suleiman GS, Accetturi C, Leite OM, Abreu WB, Kalichman AO, Moraes-Filho JP, Motti EF, Pecoraro ML, Makurath MR, Nessly ML, Leavitt RY.

Rev Inst Med Trop Sao Paulo. 2000 Jan-Feb;42(1):27-36.

Supplemental Content

Loading ...
Support Center